BIIB - Picture Perfect Market Maker ModelQuite Frankly This Is a Piece of Art.
Ai is been helping Bio Tech massively
Using the 3 Month and 1 Month Time frames we have a perfect Market maker model. Consolidation up top with market manipulation straight to distribution (A,M,D)
- 2 main accumulations before it hit's a perfect fair value g
Key facts today
BMO Capital has adjusted its price target for Biogen (BIIB) from $139 to $128.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
233.83 MXN
34.03 B MXN
193.20 B MXN
145.62 M
About Biogen Inc.
Sector
Industry
CEO
Christopher A. Viehbacher
Website
Headquarters
Cambridge
Founded
1978
FIGI
BBG00JX0Q3Q8
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
BIIB Long, Coming Soon!The price has sold off from the $207.59 pivot level, dropping to $193.84 as of the Monday, September 30th close. The sharp decline from $200 to $190 over two days last week was largely due to sector-wide weakness, as reflected in the IBB (Biotech ETF). Since then, both the ETF and BIIB have been con
Biogen Stock Surge 4.85% on Approval For ALS DrugBiogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical need
Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 cu
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050Yield to maturity
7.82%
Maturity date
May 1, 2050
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
7.72%
Maturity date
Feb 15, 2051
US9062XAD5
BIOGEN INC. 15/45Yield to maturity
6.70%
Maturity date
Sep 15, 2045
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030Yield to maturity
5.31%
Maturity date
May 1, 2030
IDPC
BIOGEN INC. 15/25Yield to maturity
5.06%
Maturity date
Sep 15, 2025
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
4.65%
Maturity date
Feb 15, 2051
See all BIIB bonds
Curated watchlists where BIIB is featured.
Related stocks
Frequently Asked Questions
The current price of BIIB is 2,860.00 MXN — it has increased by 2.69% in the past 24 hours. Watch BIOGEN INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange BIOGEN INC stocks are traded under the ticker BIIB.
We've gathered analysts' opinions on BIOGEN INC future price: according to them, BIIB price has a max estimate of 6,825.94 MXN and a min estimate of 2,415.03 MXN. Watch BIIB chart and read a more detailed BIOGEN INC stock forecast: see what analysts think of BIOGEN INC and suggest that you do with its stocks.
BIIB stock is 3.23% volatile and has beta coefficient of 0.49. Track BIOGEN INC stock price on the chart and check out the list of the most volatile stocks — is BIOGEN INC there?
Today BIOGEN INC has the market capitalization of 336.82 B, it has decreased by −6.71% over the last week.
Yes, you can track BIOGEN INC financials in yearly and quarterly reports right on TradingView.
BIOGEN INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
BIIB earnings for the last quarter are 71.72 MXN per share, whereas the estimation was 69.46 MXN resulting in a 3.26% surprise. The estimated earnings for the next quarter are 65.32 MXN per share. See more details about BIOGEN INC earnings.
BIOGEN INC revenue for the last quarter amounts to 51.18 B MXN, despite the estimated figure of 50.21 B MXN. In the next quarter, revenue is expected to reach 45.88 B MXN.
BIIB net income for the last quarter is 5.56 B MXN, while the quarter before that showed 7.65 B MXN of net income which accounts for −27.33% change. Track more BIOGEN INC financial stats to get the full picture.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 17, 2025, the company has 7.61 K employees. See our rating of the largest employees — is BIOGEN INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC EBITDA is 58.32 B MXN, and current EBITDA margin is 30.19%. See more stats in BIOGEN INC financial statements.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC stock shows the sell signal. See more of BIOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.